With record-breaking investment, faster regulatory pathways, and stronger returns, the US has become the next strategic move for many European life sciences companies. But success in this market isn’t just about timing - it’s about understanding what’s different and planning accordingly. This guide breaks down the opportunities, challenges, and critical factors behind a successful US expansion strategy in 2025.
Why this report matters
From FDA credibility to funding access and proximity to innovation hubs, the US market offers enormous upside, but it also brings fierce competition, high operational costs, and cultural differences that can’t be ignored.
This guide helps you weigh the pros and cons with clarity and confidence, so you can decide if (and when) US expansion is the right next step.
Whether you’re planning your first hire stateside or preparing to scale a commercial team, this is essential reading.
What’s inside the report
- Key market comparisons between the EU and the US in healthcare spend, talent access, and regulation
- Funding opportunities and how EU companies are unlocking capital in the US
- Regulatory insights, including FDA fast-track options and credibility signals
- Challenges to watch from cost structure to cultural fit
- Real-world advice on building local teams, securing investment, and launching successfully
If you're exploring US expansion in 2025, this guide gives you the strategic insight to move forward with focus.
Download eBook